The analysis examined overall program counts as well as distribution by development stage, drug modality, and therapeutic area. Growth in early-stage development was observed across multiple countries ...
As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no ...
In 2015, about 48% of early-stage programs originated in the U.S. and 8% in China. By 2024, the U.S. share had declined to just over 37%, while China's share rose to just over 32%. Overall, the number ...
WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...